Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMIS 25 mg in prostate cancer
2017-001333-88Phase 3Completed
- Sponsor
- Foresee Pharmaceuticals
- Start
- Jul 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of leuprolide in prostate cancer (PCa), sponsored by Foresee Pharmaceuticals. Primary endpoints: Serum testosterone suppression at week 4, Maintenance of testosterone suppression through week 24 and 1 more. Started Jul 2017; status: completed.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2017-001333-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001333-88.